Abstract | Most patients who die of cancer have disseminated disease that has become resistant to multiple therapeutic modalities. Ample evidence suggests that the expression of ATP-binding cassette (ABC) transporters, especially the multidrug resistance protein 1 (MDR1, also known as P-glycoprotein or P-gp), which is encoded by ABC subfamily B member 1 (ABCB1), can confer resistance to cytotoxic and targeted chemotherapy. However, the development of MDR1 as a therapeutic target has been unsuccessful. At the time of its discovery , appropriate tools for the characterization and clinical development of MDR1 as a therapeutic target were lacking. Thirty years after the initial cloning and characterization of MDR1 and the implication of two additional ABC transporters, the multidrug resistanceassociated protein 1 (MRP1; encoded by ABCC1)), and ABCG2, in multidrug resistance, interest in investigating these transporters as therapeutic targets has waned. However, with the emergence of new data and advanced techniques, we propose to re-evaluate whether these transporters play a clinical role in multidrug resistance. With this Opinion article, we present recent evidence indicating that it is time to revisit the investigation into the role of ABC transporters in efficient drug delivery in various cancer types and at the blood-brain barrier.
1
, most patients with metastatic cancer will die from multidrugresistant disease. Development of multidrug resistance -the acquisition of resistance to multiple, structurally unrelated compounds -is a frequent problem in the treatment of cancer and should be distinguished from resistance to anticancer drugs with precise targets and immune therapies that are not examples of multidrug resistance. There are several extensive reviews detailing the history and development of this field [2] [3] [4] [5] . Acquired multidrug resistance has been intensively studied, and the basic science is well established. Over 50 years ago, a HeLa subline was described that exhibited actinomycin D resistance following selection in 0.1 µg ml −1 of the drug 6 . When Chinese hamster lung and fibroblast cells were grown is multidrug resistance protein 1, MDR1. The murine homologue was found to confer resistance to doxorubicin, colchicine and vincristine when transfected into drug-sensitive LR23 hamster cells 13 . These seminal findings launched the study of ABC transporters, with a family of 48 human membrane transporters identified and shown to be involved in diverse physiological processes 14 .
The second member of the ABC transporter family that was identified, multidrug resistance-associated protein 1 (MRP1), encoded by ABCC1, was first reported in 1992 (ref. 15 ). It was found in cell line models to mediate resistance to doxorubicin, etoposide and vincristine among others 16 , but evidence of ubiquitous expression and lack of convincing evidence that it plays a role in clinical drug resistance has meant it is unlikely to be a suitable target for anticancer therapy. The third member of the ABC transporter family that was identified, ABCG2 (also known as breast cancer resistance protein, BCRP), encoded by ABCG2, was reported by three different groups within the span of a few months [17] [18] [19] . These findings increased interest in the study of ABC transporters but added complexity to the definition of multidrug resistance. Although the substrates and key roles for most of these transporters have been identified, the extent to which these transporters play a role in clinical multidrug resistance has not been clarified yet. Despite the clinical failure of MDR1 inhibitors, recent evidence suggests that expression of ABC transporters plays a role in clinical multidrug resistance in some settings. In the following sections, we argue that a contemporary understanding and reanalysis of target biology and the identification and development of efficient biomarkers using advanced technologies could identify settings in which transporters involved in multidrug resistance could be considered important therapeutic targets.
Structure and function
The 48 human ABC transporter genes are classified into seven subfamilies (termed ABC subfamily A through ABC subfamily G) 20, 21 . Structurally, ABC transporters are typified by a characteristic four-domain in actinomycin D to select for resistance, the selected cells were resistant not only to actinomycin D but also to vinblastine, vincristine and daunomycin 7 . Another study showed that the agent daunomycin was actively transported out of multidrugresistant mouse Ehrlich ascites cells, suggesting the existence of a promiscuous membrane transporter that confers multidrug resistance 8 . This transporter was later identified in multidrug-resistant Chinese hamster ovary cells and called 'P-glycoprotein' because transporter expression was associated with altered drug permeability in resistant cells 9 . The gene encoding P-glycoprotein in Chinese hamster ovary cells was subsequently cloned 10 ; the human homologue was reported soon after and the gene termed multidrug resistance (MDR) in the respective study 11, 12 . The human gene is from here on referred to as ATP-binding cassette (ABC) subfamily B member 1, ABCB1, and its protein product architecture consisting of two cytoplasmic nucleotide-binding domains (NBDs) that bind and hydrolyse ATP and two transmembrane domains (TMDs) that recognize and transport substrates ( fig. 1a) .
Whereas the structure and function of NBDs are similar throughout families, TMDs are highly heterogeneous, allowing transporters to recognize diverse substrates and use the energy from ATP hydrolysis to translocate molecules across membranes, irrespective of the prevailing concentration gradient 22 . Recent work suggests that while the energy from ATP can help translocate engaged substrates, basal ATP hydrolysis drives a continuously changing conformation that may facilitate MDR1 binding and transport of a wide range of substrates 23 ( fig. 1b) .
High-resolution structures of MRP1 (ref.
24
) and ABCG2 (ref.
25
) determined using cryo-electron microscopy have helped to clarify the drug-binding domains but have left the precise translocation mechanism unresolved.
ABC transporters regulate cellular levels of hormones, lipids, ions, xenobiotics and other small molecules by transporting molecules across cell membranes and serve a range of physiological roles, including intracellular regulation of organelles such as the mitochondrion 26 , lysosome 27 , endoplasmic reticulum 28 and Golgi apparatus 29 . Loss of function of a particular ABC transporter via germline mutation is associated with a number of heritable diseases, including cystic fibrosis (associated with mutation of cystic fibrosis transmembrane conductance regulator (CFTR), encoded by CFTR (also known as ABCC7)), pseudoxanthoma elasticum (associated with mutation of MRP6, encoded by ABCC6), Stargardt macular degeneration (associated with mutation of ABCA4), Tangier disease (associated with mutation of ABCA1), sitosterolaemia (associated with mutation of ABCG5 or ABCG8) and harlequin ichthyosis (associated with mutation of ABCA12) 30 .
The research and management of these disorders present considerable biological and clinical challenges, as the development of small molecules or gene therapy is required that enables normalization of mutant transporters via strategies such as ribosomal readthrough, stabilization of messenger mRNA 31 , correction of folding defects 32 , correction of trafficking defects 33, 34 , allosteric activation 35 , modulation of protein-protein interactions 36 , control of post-translational regulation 37 , regulation of protein degradation pathways 37, 38 or induction of compensatory mechanisms 39 . Prospects are improved somewhat given that restoration of activity to as little as 5% of that of wild-type basal activity can be sufficient to partially ameliorate disorder phenotypes 40, 41 . It should be noted that among the 48 ABC transporters, some have very narrow substrate specificity, whereas others have a broad substrate specificity. It is the transporters with broad substrate specificity that have the potential to transport a range of anticancer agents, and the expression level of these 25 (PDB ID 5NJ3), multidrug resistance protein 1 (MDR1) 23 (PDB ID 5KPI) and multidrug resistance-associated protein 1 (MRP1) 24 (PDB ID 5UJ9). Although the structure for MRP1 is that of Bos taurus, the protein identity is 91%, and the structure is likely similar to that of human MRP1. Structures were generated using PyMol 138 with data from RCSB PDB (see Related links).
b | Schematic representation of the proposed pumping action of MDR1. The substrate binds to the binding pocket, and ATP binds to the two binding sites in the nucleotide-binding domains (NBDs). This is followed by the hydrolysis of ATP, which generates a conformational change, allowing the substrate to be released from the protein. The second molecule of ATP is hydrolysed, allowing for a conformational reset where substrate and ATP can bind again so the process can repeat.
transporters in tumour cells may determine the ability to confer drug resistance 42 . It has been difficult to determine which transporters deserve the most scrutiny to define their role in multidrug resistance, as the use of cell lines with high ABC transporter expression levels in some cases led to an overestimation of their role in cancer. The reader is referred to several reviews compiling substrate lists of a range of transporters [43] [44] [45] . One detailed compilation notes that 19 of the 48 ABC transporters have been shown to efflux anticancer agents in some context 43 . We focus on the subset of ABC transporters that were first reported as multidrug efflux pumps (MDR1, MRP1 and ABCG2), what we have learned about their basic science, how clinical application has faltered and what might constitute a path forward, focusing on the most recent work in this field.
MDR1, MRP1 and ABCG2 have excretory and/or protective physiological capacities by transporting substrates across biological membranes. At the blood-brain barrier (BBB), the bloodtestis barrier and the blood-placental barrier, expression of ABC transporters in the capillary endothelial cells serves to prevent entry of exogenous molecules 46, 47 . A consequence of these protective roles is that these transporters can affect pharmacokinetic parameters of drug absorption, distribution, metabolism, excretion and toxicity 48 . Inhibition of ABC transporters often leads to toxicities or pharmacokinetic changes owing to drug-drug interactions 48 , and the US Food and Drug Administration (FDA) offers guidance on how investigational drugs should be characterized with regard to their ability to interact with ABC transporters 49 .
The multidrug resistance hypothesis Nearly 40 years of findings from cell culture and animal models indicate that the efflux activity of ABC transporters mediates multidrug resistance. The potential importance of ABC transporters in multidrug resistance is illustrated by the numerous anticancer agents that have been identified as substrates, including anthracyclines, taxanes, vinca alkaloids, camptothecins, epipodophyllotoxins and tyrosine kinase inhibitors 1, 50 . Although there is considerable overlap among the substrate profiles of the various ABC transporters, there are some differences. MRP1 has been shown to transport various neutral and anionic hydrophobic compounds and products of phase II drug metabolism, including many glutathione and glucuronide conjugates 51 . ABCG2 transports the anticancer drugs methotrexate, mitoxantrone, topotecan, irinotecan and flavopiridol 52 . In addition to efforts to define ABC transporter structure and function, efforts have been made to define the clinical roles of ABC transporters in multidrug resistance, primarily for MDR1, the first transporter to be discovered. These studies generally used RNA-based or immunohistochemical methods of detection and examined association with outcomes 53 . Numerous studies reported the presence of MDR1 mRNA and protein in clinical samples -in leukaemias and in kidney, colon, breast and lung cancers -and, typically, MDR1 expression portendeds a poor response to chemotherapy [53] [54] [55] . These results led to the development of clinical trials to test the multidrug resistance hypothesis that inhibitors of MDR1 could improve response to chemotherapy and outcome via increased drug accumulation mediated by inhibition of drug transport 56, 57 .
Targeting MDR1
After the discovery of MDR1, a number of first-generation inhibitors, including verapamil, quinidine, amiodarone and cyclosporine A, were identified and added to chemotherapy regimens in clinical trials 56 . However, these agents were not very potent or were toxic in their own right, and their ability to inhibit MDR1 was not verified in patients 5 . The second-generation agents valspodar and dexverapamil were more potent MDR1 inhibitors 56 . Surrogate assays were used to confirm that serum concentrations of inhibitors such as valspodar were adequate to inhibit rhodamine 123 transport in MDR1-positive circulating CD56 + cells after inhibitor administration 58, 59 . However, at that point in time, neither the expression nor the function of MDR1 in tumours had been verified, nor whether the inhibitors actually blocked drug efflux in tumour cells. Additionally, pharmacokinetic interactions with the inhibitors, such as the inhibition of cytochrome P450 by valspodar, required chemotherapy dose reductions, leading to potential underdosing of patients 60 . A third generation of inhibitors, including dofequidar, zosuquidar, tariquidar, elacridar and biricodar, were developed specifically as MDR1 inhibitors. These were more potent and displayed fewer pharmacokinetic interactions than inhibitors of previous generations but caused some toxicity in combination with chemotherapy, potentially owing to inhibition of MDR1 expressed in normal tissue 57 . Importantly, some showed cross reactivity with MRP1 and/or ABCG2 (refs [61] [62] [63] [64] ). Elacridar and tariquidar were found to inhibit both MDR1 and ABCG2 (refs 61,64 ) while cyclosporine A and biricodar were found to inhibit MDR1, MRP1 and ABCG2 (refs 62,63 ). Interestingly, the combination of cyclosporine A with chemotherapy led to increased response in acute myeloid leukaemia (AML) in one study 65 ; however, these results could not be duplicated in studies with other inhibitors 66 . Unfortunately, despite a few early successes, the majority of clinical trials with MDR1 inhibitors, even third-generation inhibitors, did not confirm clinical benefit 57 .
The lack of success of these inhibitors in clinical trials resulted in a nearly complete shutdown of study in the field after these trials were completed, and the clinical validation and development of specific inhibitors for other ABC transporters potentially involved in multidrug resistance was not pursued. Further clinical trials using MDR1 inhibitors were vehemently discouraged 67 . However, some experimental work on mechanistic and functional aspects of ABC transporters continued, including efforts to define substrates and inhibitors of ABC transporters, the role of ABC transporters in the BBB and the role of ABC transporters in pharmacology. As noted above, the FDA now offers guidance on measuring the interaction of novel therapies with ABC transporters during clinical development 49 because ABC transporters can be critical determinants of drug pharmacokinetics, including oral availability, drug-drug interactions and drug toxicity. Of note, recent reports of unexpected toxicity in response to chemotherapy combined with receptor tyrosine kinase (RTK) inhibitors may be explained by interactions of RTK inhibitors with ABC transporters [68] [69] [70] . Indeed, several RTK inhibitors, such as lapatinib, apatinib and nilotinib, have been shown to inhibit ABC transporters [71] [72] [73] , whereas some, such as ceritinib, crenolanib and imatinib, were found to be substrates of ABC transporters [74] [75] [76] . In some cases, these interactions might be beneficial. For example, when patients were treated with the chemotherapeutic agent topotecan in combination with the RTK inhibitor pazopanib, total topotecan exposure in these patients was 1.7-fold higher than in patients treated with topotecan alone. This was primarily because pazopanib inhibits ABCG2, thus increasing the absorption of orally administered topotecan 77 . Unfortunately, these studies did not confirm the role of transporter-mediated reduced drug accumulation in clinical drug resistance. However, gene expression, gene mutation and single-nucleotide polymorphism (SNP) studies have provided new evidence supporting the potential benefit of a re-examination of ABC transporters in clinical drug resistance. Additionally, the use of genetically engineered mouse models (GEMMs) has provided new impetus for examining the role of ABC transporters in acquired resistance to certain drugs, such as doxorubicin, topotecan and some poly(ADP-ribose) polymerase (PARP) inhibitors. Imaging studies and mouse models examining the role of ABC transporters in the gastrointestinal tract and at the BBB have consistently demonstrated that the activities of MDR1 and ABCG2 are significant impediments to anticancer agent oral absorption and brain exposure 78 . A summary of the new evidence supporting the role of ABC transporters in drug resistance is given in the next section.
ABC transporters in resistance MDR1 overexpression is associated with resistance in some tumour subsets. Many of the early clinical trials to test the MDR1 hypothesis were designed for patients with AML 56 . Although largely unsuccessful, we now recognize their design was optimistic and success unlikely given that the focus was only on MDR1, and patients were not selected based on MDR1 expression or potential MDR1 involvement in the patient's resistance to therapy 55 . For example, gene expression profiling in 170 AML samples showed that only 13% of the samples were refractory and positive for ABCB1 or ABCG2 expression 79 . Whole-genome sequencing of 92 patients with high-grade serous ovarian carcinoma with primary and matched resistant disease showed that amplification of cyclin E1 (CCNE1) and reversion of BRCA1 and/or BRCA2 mutations were potential mechanisms of resistance. Interestingly, the authors also found recurrent promoter fusions associated with overexpression of ABCB1 (ref.
80
). These promoter fusions, occurring in about 8% of patients with resistant disease, lead to ABCB1 overexpression. The underlying gene rearrangements place a more active promoter at the 5′ end of the ABCB1 transcript 81, 82 ( fig. 2 ). These gene rearrangements are monoallelic, with the remaining alleles being transcribed normally 81, 82 . This mechanism has first been reported in cell culture models and in clinical samples from patients with refractory acute lymphoblastic leukaemia 81, 82 . Of note, paclitaxel and docetaxel, the main therapies used in ovarian cancer, which were administered to patients in this study before recurrence, are substrates of MDR1 (ref.
).
In our view, these observations suggest that the ABCB1 gene rearrangements were selected for in the drug-resistant phenotype; however, the low occurrence rate of these gene rearrangements argues that they might occur only in a particular molecular background. As previously reported using a TaqMan low-density array, only a small percentage of ovarian cancers show high levels of ABCB1 expression after paclitaxel or docetaxel treatment 83 . These studies suggest that patient selection in any clinical trial targeting MDR1 should include validation of MDR1 expression in the patients' tumours.
In a recent observation, investigators identified unexpectedly high levels of ABCB1 in samples obtained from a patient whose anaplastic lymphoma kinase (ALK)-rearranged lung cancer had developed resistance to ceritinib, a drug used to treat lung cancers with mutations in the ALK gene, without a new ALK mutation. The investigators established cell lines from different metastatic sites in this patient and found that both the post-ceritinibtreated tumour and cell lines derived from it exhibited high levels of MDR1 (ref.
74
The authors also found that MDR1 was highly expressed in 3 of 11 ALK-rearranged refractory lung cancers in which secondary ALK mutations were absent 74 , indicating a correlation between MDR1 expression and ceritinib resistance. Importantly, owing to a lack of analytical tools, lung cancer studies conducted with MDR1 inhibitors in the 1990s 2 could not have envisioned the subset stratification that would be needed to find the small subset of patients in whom MDR1 is both highly expressed and likely to confer drug resistance.
Expression of multiple ABC transporters.
It is now clear that multiple ABC transporters may be expressed in a single tumour type. A study that examined expression of all 48 human ABC transporters in 281 AML samples found in a multivariate analysis that expression of ABCB1, ABCG1 and ABCG2 was linked to overall survival, and the overall survival decreased with increasing number of transporter genes co-expressed 84 . Similar results were observed in childhood AML, where ABCA3, ABCB1, ABCC3 and ABCG2 mRNA expression levels were measured by real-time PCR, and the increasing number of co-expressed ABC transporters correlated with shorter relapse-free survival 85 . Finally, in a set of 11 paired samples taken from patients with AML at diagnosis and relapse, a twofold overexpression of at least one ABC transporter capable of transporting anthracyclines or vinca alkaloids was found in ten of the paired samples 86 . Although the links between ABC transporter coexpression and clinical outcome are correlative and have not been shown to be causal, together these results suggest that inhibition of multiple transporters might be required to achieve clinical benefit. This may be especially true for primitive leukaemic CD34 +
CD38
-cells, the putative stem cell population. This cell population has been shown to express high levels of ABCG2 as well as potentially MDR1 and MRP1 in some patient samples 87 . Expression of ABCG2 and MDR1 in this cell population has been found to correlate with response to chemotherapy both clinically and when measured ex vivo in leukaemic blast samples 88 . It remains to be determined whether all or a subset of these ABC transporters may be involved in the efflux of anticancer drugs in the clinical setting. Support for the idea that the expression of multiple ABC transporters correlates with a resistance phenotype has also been found in solid tumours. A study of all ABC transporters in pancreatic cancer found significant upregulation of ABCB4, ABCB11, ABCC1, ABCC3, ABCC5, ABCC10 and ABCG2 at the mRNA level in macrodissected tumours relative to normal tissue, although the study did not attempt to correlate transporter expression with chemotherapy response 89 . However, the fact that tumour samples were not microdissected may be a confounding factor. ABCB1 mRNA, which is physiologically expressed at high levels in cells of the pancreatic duct and acinar cells 90 , was not upregulated in tumour tissue compared with normal tissue. Upregulation of ABC transporter expression beyond the high levels found in normal tissue may not be necessary to confer drug resistance, as in hepatocellular carcinoma, where expression levels of multiple ABC transporters have been reported to be similar to the already high levels of expression in normal liver cells 91, 92 . With the advent of genomic analysis, we have an unbiased approach to measuring ABC transporter mRNA expression. It is now possible to measure expression of all transporters simultaneously rather than focusing on certain transporters that we hypothesize might be involved in resistance. Analysis of RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) database found that expression of both ABCB1 and ABCG2 in a variety of tumour types ranges over 1,000-fold ( fig. 3) , a far greater range of expression than was reported in studies using older technologies. Although a frequent criticism of early MDR1 studies was that in vitro levels of ABCB1 are much higher than those found in patient tumours 93 , this broad range suggests very high levels in some tumours. However, it has been reported that in the case of some tumours, such as breast cancer, ABCB1 expression is found primarily in tumour-associated macrophages and not in the tumour samples themselves 94 , and high stromal expression of ABC transporters could skew expression values in RNA-seq data from tumour samples. Discordance between RNA and immunohistochemical data is thought to be responsible for this problem in some cases 95 , but doubts in regards to antibody specificity have also been expressed 96 . (fig. 3) . While RTK inhibitors are approved for the treatment of both of these types of cancer 97 , these cancer types show frequent resistance to the mainstay chemotherapeutics such as vincristine and doxorubicin, which are MDR1 substrates 53 . Of note, the ability to detect RNA transcript levels more accurately via newer technologies does not really overcome the deficiencies in our understanding of the role of ABC transporters in multidrug resistance. These deficiencies include the lack of a direct demonstration of how ABC transporter activity affects drug accumulation in cancer cells and the clinical significance of that activity.
The studies outlined above indicate that only a fraction of cancers express ABC transporters at levels that could potentially be linked to drug resistance. MDR1 is expressed in only 13% of AML, 8% of ovarian cancers and 30% of ALK-positive non-small-cell lung carcinoma samples, suggesting that MDR1 should have been targeted as cancer mutations are today, where patients are carefully screened and selected for expression of the target in tumour cells. In addition, expression of more than one ABC transporter is common. Clinical studies of MDR1 inhibitors in the past did not routinely include molecular characterization of tumour tissues 56 and thus were likely confounded by the inclusion of patients who had low tumour levels of MDR1, and in whom MDR1 inhibition would have had no predicted clinical benefit.
Single-nucleotide polymorphism studies to determine the role of ABC transporters.
One way to determine whether MDR1 plays a role in anticancer drug resistance is to evaluate the impact of polymorphic variants on chemotherapy response or cancer outcome. Polymorphic variants of ABC transporter genes that impair substrate efflux could be associated with a higher cancer [98] [99] [100] [101] . The largest and most reliable SNP association study to date was based on RNAseq data derived from the TCGA database, examining RNA sequence and expression data from 4,616 ovarian cancer patients who had received any form of adjuvant chemotherapy 102 . In particular, the correlation of three common coding SNPs tagging either C1236T (rs1128503), G2677T/A (rs2032582) or C3435T (rs1045642) of ABCB1 in patients with prior chemotherapy was determined 102 , and only a marginal association of C1236T with improved overall survival was found. The study also reported that ABCB1 mRNA overexpression in 143 serous ovarian tumours was associated with a worse prognosis in suboptimally debulked patients 102 .
Transporter expression in mouse models of acquired resistance. Expression of ABC transporters emerged as the principal mechanism of resistance in an elegant series of studies involving a GEMM of hereditary breast cancer that arises in the mammary epithelium of mice deficient for Brca1 and Trp53 (ref.
103
). Treatment of animals from this model with the maximum tolerable dose of docetaxel or doxorubicin, both MDR1 substrates, led to an initial differential response in mice, but, eventually, all tumours became resistant to treatment. Gene expression analysis was subsequently performed on 13 doxorubicin-resistant tumours, and upregulation of mRNA expression levels of Abcb1a and/or Abcb1b (the murine orthologues of ABCB1) were found in 11 of the 13 tumour samples compared with the matched, sensitive tumours 103 . These doxorubicin-resistant tumours were also resistant to docetaxel. In a subsequent study, transport of 99mTc-MIBI, a contrast agent used in cardiac imaging that is a substrate of MDR1 (ref.
104
), was also demonstrated in mice harbouring the doxorubicin-resistant tumours generated from the mice described above 103 that overexpressed Abcb1a and Abcb1b but not in control tumours 105 . Similar results were obtained when the mice deficient in Brca1 and Trp53 were treated with the PARP inhibitor olaparib: all tumours responded initially to a 28-consecutiveday treatment, but, eventually, all tumours acquired resistance. When compared with their olaparib-responsive counterparts, recurring tumours overexpressed Abcb1a and/or Abcb1b
106
. The addition of tariquidar to olaparib treatment resensitized tumours expressing Abcb1a and/or Abcb1b to olaparib, indicating a role of MDR1 in olaparib resistance in these tumours, whereas the addition of tariquidar alone had no effect on growth 106 . In doxorubicin-resistant tumours arising in this model, moderate increases in MDR1 expression -as little as twofold compared with treatment-naive tumourswas found in 11 of 13 tumours compared with untreated tumours. In some of these resistant tumours, resistance to doxorubicin could be overcome by the addition of tariquidar to doxorubicin treatment, whereas tariquidar itself had no effect 107 . In a separate study using the same mouse model, when tumour-bearing mice were treated with the topoisomerase I inhibitor topotecan, heterogeneous responses were observed, but, eventually, all tumours developed resistance to topotecan 108 . Of the 20 topotecan-resistant tumours that were examined, 9 expressed at least twofold higher levels of Abcg2 compared with matched untreated control tumours. When Abcg2-null alleles were introduced into the mice deficient in Brca1 and Trp53, the resulting tumours were transplanted into syngeneic wild-type animals, which were subsequently treated with topotecan. Mice bearing tumours deficient in Brca1, Trp53 and Abcg2 had an increased overall survival compared with mice bearing tumours deficient in Brca1 and Trp53 and expressing Abcg2, suggesting that Abcg2 contributed to topotecan resistance in this model 103 . Of note, expression of Abcc1 and Abcc4, which have also been implicated in topotecan resistance, were not found to be increased in resistant tumours compared with matched untreated control tumours 108 . In order to test the efficacy of the ABCG2 inhibitor Ko143 on topotecanresistant Brca1 and Trp53-deficient tumours that overexpressed Abcg2, tumours were transplanted into Abcg2-deficient mice so as to overcome the effects of Abcg2 on topotecan clearance 109 . Compared with tumours treated with topotecan alone, the addition of Ko143 was not able to completely overcome tumour resistance to topotecan, as overall survival only moderately increased from 52 to 71.5 days. This could be due to the short plasma half-life of Ko143. To further explore the role of Abcg2 in drug resistance, the efficacy of EZN-2208 (a pegylated form of SN-38) was compared with irinotecan. The active metabolite of EZN-2208, SN-38, is an ABCG2 substrate 108 . Pegylation of SN-38 allows for sustained release of SN-38 and may overcome ABCG2-mediated resistance 108 . Overall survival of mice treated with EZN-2208 was doubled compared with mice treated with irinotecan alone 108 , suggesting that thwarting the activity of ABCG2 increases sensitivity to substrate drugs.
Similar observations have been reported in other GEMMs. In a mouse model of mammary tumours deficient in Brca2 and Trp53, Abcb1a and/or Abcb1b expression was higher in three of four chemo-naive tumours with a sarcomatoid phenotype, referred to as carcinosarcoma, compared with the carcinomas that predominantly arise from this model; all carcinosarcomas expressed higher levels of Abcg2 compared with the carcinomas 110 . Additionally, when four treatment-naive carcinosarcomas were treated with the maximum tolerated dose of topotecan, docetaxel, doxorubicin or olaparib, none of the tumours responded 110 . When mice bearing the carcinosarcoma with the highest level of Abcb1a and Abcb1b were treated with olaparib, docetaxel or doxorubicin in the presence of tariquidar, significantly higher growth delay was observed compared with mice treated with chemotherapy or tariquidar alone 110 . After genetically sequencing a panel of ten carcinomas and four carcinosarcomas derived from this same model, unsupervised clustering was performed using an epithelial-to-mesenchymal transition (EMT) genetic signature 110 . Interestingly, the carcinosarcomas, which express higher levels of Abcb1a, Abcb1b and Abcg2, were found to have higher expression of mesenchymal genes and lower expression of epithelial genes 110 . An examination of ABCB1 expression in human triple-negative breast cancer samples mined from a previous study 111 demonstrated that tumours with an EMT phenotype (low expression of the EMT marker claudin) had high basal levels of ABCB1 expression compared with basal-like tumours 112 . Despite these elegant studies in mice that implicate MDR1 as a potential resistance mechanism in breast cancer, the role of MDR1 in mediating resistance has not been as clearly implicated in human breast cancer.
The inability to translate MDR1 data derived from mouse models to humans could be because basal levels of MDR1 are higher in rodents than in humans, which then translates to MDR1 expression in response to anticancer drug treatment in rodents 113 . Another explanation is that relatively small increases in MDR1 expression, which could be clinically important, might not have been detected owing to methodological limitations such as the technique used to determine MDR1 expression 113 . To overcome the limitations of animal models in preclinical target characterization, human breast epithelial organoids could be used to verify data derived from animal models 114 .
Decreased oral bioavailability owing to ABC transporter activity. Although not directly involved in drug resistance, ABC transporter expression in the gastrointestinal tract is known to affect the oral bioavailability of some chemotherapy drugs that are ABC transporter substrates. This has been shown for taxanes and topotecan, which are not given orally owing to interactions with MDR1 and ABCG2, respectively. The dual MDR1 and ABCG2 inhibitor elacridar has been combined in exploratory trials with oral taxol 115 or topotecan 116 to increase oral bioavailability in patients; however, the clinical efficacy of these combinations has not been reported. The expression of ABC transporters in the gastrointestinal tract might have the potential to cause drug resistance. For example, when Caco-2 intestinal cells were chronically exposed to imatinib, MDR1 and ABCG2 expression was induced 117 . If this were to occur in the gastrointestinal tract, it would limit oral availability of imatinib, resulting in lower serum concentrations and resistance to the drug, although this has yet to be demonstrated in vivo or in the clinic.
ABC transporters at the blood-brain barrier limit drug uptake. One of the stunning discoveries made during the evolution of this field was the critical importance of MDR1 at the BBB, which was first shown in mouse models in which deletion of Abcb1a and Abcb1b resulted in central nervous system (CNS) toxicity from ivermectin, an antiparasitic commonly used on animals 118 . After the discovery of ABCG2, mice lacking Abcb1a, Abcb1b and Abcg2 were generated 78 . A systematic series of investigations demonstrated the often overlapping and synergistic role of these two transporters in restricting the entrance of anticancer therapeutics to the brain in mouse models in which brain concentration of these therapeutics is measured in wildtype versus ABC transporter-deficient mice 78 ( fig. 4) .
The deletion of either Abcb1a and Abcb1b or Abcg2 alone or in combination typically has only minimal effects on systemic blood levels of their substrates, though steady-state brain levels of substrates are markedly higher when both transporters are deleted rather than either alone 78 . ), ABC subfamily G member 2 (Abcg2) or all three (triple knockout (TKO)) transporters is compared with wild-type mice, which are assigned a value of 1. White blocks denote mice not studied. ALK , anaplastic lymphoma kinase; CDK, cyclin-dependent kinase; EGFR , epidermal growth factor receptor ; EZH2, enhancer of zeste homologue 2; HER2, human epidermal growth factor receptor 2; MDR1, multidrug-resistance protein 1; PARP, poly(ADP-ribose) polymerase; VEGF, vascular endothelial growth factor ; WT, wild type. Figure adapted with This result is not surprising because the C421A polymorphism adversely affects the activity of ABCG2 (refs 127,128 ).
[N-methyl- Finally, D-luciferin, the substrate for firefly luciferase, was shown to be transported by ABCG2 (ref.
132
) and was subsequently shown to be selectively transported by ABCG2 rather than MDR1 or MRP1 (ref. ]dLop) is a specific substrate of MDR1 that cannot pass through the blood-brain barrier (BBB) when MDR1 is active; that is, no radio signal in the brain can be observed. Upon inhibition or knockout of MDR1, high signal intensity in the brain is observed, whereas inhibition of ATP-binding cassette (ABC) subfamily G member 2 (ABCG2) has no effect. In the instance of a dual substrate of both MDR1 and ABCG2 such as [ 11 C]erlotinib, specifically blocking either MDR1 or ABCG2 results in a minimal increase in brain signal, and only dual inhibition or knockout produces an effect. An alternative imaging strategy is presented by using the specific ABCG2 substrate D-luciferin, with transgenic mice expressing firefly luciferase in astrocytes. Brain bioluminescence signal was low , and specific inhibition of ABCG2 but not MDR1 produced an elevated signal. Third-generation inhibitors, such as tariquidar and elacridar, are considered to primarily inhibit MDR1, while Ko143 (which has not been used in humans) acts primarily on ABCG2. No gold-standard probe for dual inhibition of ABCG2 and MDR1 exists. These imaging tools can act as the basis for studies of multidrug resistance in tumours and efficacy and dose optimization of new inhibitors.
in increased bioluminescent signal in mouse brains as compared with mice administered D-luciferin alone 133 ( fig. 5 ).
These studies pave the way for the use of radiotracers in patients, which can help to confirm the activity of inhibitors, monitor the brain penetration of substrate drugs and serve as possible biomarkers for assessing the multidrug resistance status of patient tumours.
Studies of the BBB have addressed the ability to target ABC transporters in patients to increase drug distribution into sanctuaries such as the brain 131 . Some investigators have attempted to demonstrate the ability to target ABC transporters in human cancers using radiolabelled substrates, particularly [ 94 Tc]sestamibi by either planar or PET imaging in patients with MDR1-expressing cancers before and after administration of an MDR1 inhibitor. Except for a small number of patients 134 , these studies have never shown the type of differential observed in laboratory models 135, 136 , but the caveats mentioned above concerning patient selection and inhibitor choice apply to these studies as well.
Although data from imaging studies are limited, they represent the one method that could be further developed to demonstrate both the impact of drug efflux and the ability to alter it and act as a biomarker for clinical trials. Such studies have been needed for a very long time, even in the absence of a strategy to inhibit MDR1.
Conclusions
Investigations into the role of ABC transporters in multidrug resistance have been encumbered by the weight of a succession of negative results from clinical trials. But evolving technology and data lead to the question of whether investigation into the role of ABC transporters in clinical drug resistance should be reopened. We argue that further investigation is indeed warranted in light of the recent data. There are various examples of the effects of MDR1 in restricting drug efficacy in patients with select cancers 74 , of MDR1 or ABCG2 expression being associated with poor clinical outcomes 79 and of gene rearrangements resulting in high expression levels of MDR1 in patients whose tumours exhibit drug resistance 80 . Adequate and consistent drug delivery has rarely been documented in clinical oncology, and results of the few studies to determine drug delivery efficacy suggest highly variable drug penetration 137 . Whether ABC transporters play a role in variable drug delivery is at present unknown. Clinical trials examining the efficacy of inhibitors of ABC transporters were conducted without selection of patients whose tumours had high levels of ABC transporter expression. With the current tools developed for advancing personalized medicine, the vision is to identify patients whose cancer cells overexpress an ABC transporter that has been shown to reduce drug efficacy in order to improve drug selection and clinical outcome. Even if we are unable to improve response to therapy by using an ABC transporter inhibitor, being able to predict clinical response to certain drugs could be seen as a valuable accomplishment.
To achieve clinical application of ABC transporters as biomarkers and as targets in combination therapy, ABC transporter expression must first be reliably detected in the tissue and/or cell type of interest, and the inhibitors used in combination with other drugs must then be safe for use in patients. Therefore, clinically validated methods to detect protein expression of the respective ABC transporters (or a highly correlated biomarker) and clinically validated imaging assays to detect ABC transporter function in tumours are needed. As argued in this Opinion article, a revival of research interest into the ABC transporter field, focusing on the most important questions of the role of drug efflux in clinical response and using advanced techniques, could potentially lead to clinical use of ATP transporters as biomarkers and therapeutic targets. 
